Risk Factors of *Clostridium Difficile* Infection After Spinal Surgery: National Health Insurance Database

Sahyun Sung¹,², Ji-Won Kwon³, Soo-Bin Lee¹, Hwan-Mo Lee¹, Seong-Hwan Moon¹ & Byung Ho Lee¹*

The purpose of this study was to evaluate risk factors of *Clostridium Difficile* infection (CDI) after spinal surgery using the Health Insurance Review and Assessment Service (HiRA) data. The incidence of postoperative CDI was investigated using HIRA data from 2012 to 2016. Cases involving CDI that occurred within a 30-day postoperative period were identified. Risk factors, including age, sex, comorbidities, postoperative infection, spinal surgery procedure, type of antibiotic, and duration of antibiotic use, were evaluated. Duration of hospital stay, medical cost, and mortality were also evaluated. In total, 71,322 patients were included. Presumed cases of CDI were identified in 57 patients, with CDI rate of 0.54 per 10,000 patient days. Advanced age, staged operation, postoperative infection, and the use of multiple antibiotics were significant risk factors. First-generation cephalosporins were shown to be associated with a lower incidence of CDI. CDI was also associated with longer hospital stays and increased medical cost, and it was an independent risk factor for increased mortality. Extra attention should be paid to patients at high risk for the development of postoperative CDI, and unnecessary use of multiple antibiotics should be avoided. Level of Evidence: Level III, retrospective cohort study.

*Clostridium difficile* (*C. difficile*) is a common pathogen responsible for approximately 10 to 25% of all cases of antibiotic-associated diarrhea¹. *C. difficile* infection (CDI) can occasionally lead to life-threatening complications, such as pseudomembranous colitis, intestinal perforation, and toxic megacolon². The incidence of CDI is increasing globally, and more than 1.1 billion dollars have been devoted to the treatment of CDI in the United States alone³.

Spinal surgery is one of the most frequently performed surgeries worldwide, and the number of spinal surgeries continues to increase annually⁴, as are the rate of complex procedures and the age of spinal surgery patients⁵. Since operative mortality and morbidity increase with increasing age and surgical invasiveness, interest in the prevention of postoperative complications has grown. Several studies have reported on CDI after spinal surgery, which can be fatal⁶-⁸. However, because of the low incidence of CDI, previous studies focused on the incidence and demographic risk factors of patients. There has not yet been a study on the effect of medication use on the development of CDI after spinal surgery, although it is well known that some types of antibiotics and gastric acid-suppressive medications are associated with CDI⁹.

In the presence of known risk factors of CDI, the prolonged use of antibiotics and broad-spectrum antibiotics could increase the incidence of CDI. Therefore, the aim of this study was to identify the incidence of CDI after spinal surgery; risk factors thereof, including the type and duration of antibiotics use; and the effect of CDI on surgical outcomes using a large, population-based, nationally representative sample.

¹Department of Orthopedic Surgery, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. ²Department of Orthopedic Surgery, College of Medicine, Ewha Womans University Seoul Hospital, Seoul, Korea. ³Department of Orthopedic Surgery, National Health Insurance Corporation Ilsan Hospital, Goyang, Korea. *email: bhlee96@yuhs.ac
Results

Of 71,322 patients, 57 were diagnosed with CDI within 30 days after surgery (incidence 0.08%). The CDI rate per total number of patient days was 0.54 per 10,000 patient days. The average time from surgery to CDI diagnosis was 18.16 ± 7.81 days. Lumbar surgery (80.68%) was the most common procedure, and the incidence of CDI therein was 0.07%. The percentage of other procedures are detailed in Table 1.

Patients who acquired postoperative CDI after spinal surgery were significantly older (67.12 ± 10.94 vs. 57.27 ± 14.78); there was no difference in sex (Table 2). The proportion of patients over 65 years of age was greater in the CDI group than in the non-CDI group (P < 0.001). CDI patients also had a higher prevalence of chronic obstructive pulmonary disease (P = 0.030) and a higher incidence of postoperative infection, such as urinary tract infection (P < 0.001), sepsis (P < 0.001), or pneumonia (P < 0.001), compared to patients without CDI. Patients with CDI were more likely to have been prescribed proton pump inhibitors postoperatively (P = 0.002); however, there was no significant difference in the use of H2 blockers between the CDI and non-CDI groups. As for the use of antibiotics, broad spectrum antibiotics were more often prescribed to CDI patients, including third generation cephalosporins (P < 0.001), fourth generation cephalosporins (P = 0.013), penicillins (P < 0.001), glycopeptides (P < 0.001), carbapenems (P = 0.009), and ketolides (P = 0.043). On the other hand, CDI patients were less likely to be given first generation cephalosporins (P = 0.004).

The effect of the duration of antibiotics use and the number of co-administered antibiotics on the incidence of CDI was investigated. (Table 3) The higher the number of administered antibiotics, the higher the incidence of antibiotics use. In multivariate analysis, independent preoperative/postoperative risk factors for postoperative CDI included greater age (most notably ≥ 65 years old, OR = 6.408, 95% confidence interval (CI) = 1.521–26.997, P = 0.011), staged operation (OR = 5.336, 95% CI = 1.417–20.087, P = 0.013), postoperative infection such as urinary tract infection (OR = 3.538, 95% CI = 1.698–7.371, P = 0.001), sepsis (OR = 4.427, 95% CI = 2.458–7.975, P < 0.001), and pneumonia (OR = 6.096, 95% CI = 2.793–13.303, P < 0.001) (Table 4). First-generation cephalosporins (OR = 0.408, 95% CI = 0.226–0.738, P = 0.003) were associated with a lower incidence of CDI. The use of three or more antibiotics was associated with higher CDI incidence (OR = 2.808, 95% CI = 1.266–6.229, P = 0.011). Third- and fourth-generation cephalosporins, penicillins, glycopeptides, carbapenems, and ketolides, which previously were shown to be associated with increased incidence of CDI, were not identified as significant risk factors for CDI in the multivariate model. The duration of antibiotics used also did not have a significant effect.

Postoperative CDI after spinal surgery resulted in remarkably negative outcomes. Mean hospitalization period increased more than three-fold for patients diagnosed with CDI versus those not diagnosed with CDI (64.91 ± 74.87 days vs. 18.85 ± 25.37 days, P < 0.001). When multiple regression analysis was performed to investigate risk factors for increased hospitalization period, CDI increased the hospitalization period by 74.02 days (P < 0.001) after adjusting for other variables. The total medical cost increased by more than four-fold for those patients with CDI diagnosis ($14,704 ± 15,590 vs. $3,580 ± 4,190, P < 0.001).

Multivariate analyses, identifying independent risk factors for mortality within 30 days postoperatively, identified CDI as a significant risk factor (OR = 7.717, 95% CI = 1.670–35.662, P = 0.009) (Table 5). In addition, the use of antibiotics, such as fourth-generation cephalosporins, penicillins, glycopeptides, and carbapenems, were associated with significantly increased odds of death, whereas the first- and second-generation cephalosporins were associated with lower risk. Advanced age and the use of three or more antibiotics were also associated with an increased odds of death.

Discussion

In this study, we found CDI after spinal surgery to be associated with advanced age, staged operation, postoperative infection, and administration of three or more antibiotics. The third-generation cephalosporins, clindamycins, penicillins, and fluoroquinolones were previously reported as risk factors for CDI[10,11]. In this study, first-generation cephalosporins were associated with a low incidence of CDI in the multivariate analysis, whereas the third- and fourth-generation cephalosporins, penicillins, glycopeptides, carbapenems, and ketolides were statistically significant risk factors in the univariate analysis alone. This may be due to the fact that, clinically, many patients are treated with more than one type of antibiotic perioperatively for broad coverage.

A previous study reported that more than 10 days of antibiotics were identified as a significant risk factor for CDI[12]; however, although higher CDI incidence was noted when antibiotics were administered for a longer period of time, the trend was not statistically significant in our study. The period of antibiotics use was calculated as the number of days the antibiotics administered regardless of the number of antibiotics used. However, antibiotic

| Procedures          | Total Cases, No. (%) | CDI, No. | Incidence of CDI (%) |
|---------------------|----------------------|----------|-----------------------|
| All spine surgical procedure | 71,322 (100%) | 57       | 0.08%                 |
| Cervical            | 9,179 (12.87%)      | 10       | 0.11%                 |
| Thoracic            | 1,282 (1.80%)       | 1        | 0.08%                 |
| Lumbar              | 59,541 (83.48%)     | 44       | 0.07%                 |
| Multilevel          | 1,320 (1.85%)       | 2        | 0.15%                 |

Table 1. Incidence of *Clostridium difficile* infection according to spinal surgery procedure. CDI: *Clostridium Difficile* infection. Multilevel indicates the simultaneous operation of two or more of the cervical, thoracic, and lumbar regions.
### Table 2. Patient characteristics, comorbidities, and prescribed medications in, with, and without *Clostridium difficile* infection. CDI: *Clostridium difficile* infection; COPD: Chronic obstructive pulmonary disease.

| Population | CDI (57) | No CDI (71,322) | P Value |
|------------|----------|-----------------|---------|
| Mean age   | 67.12 ± 10.94 | 57.27 ± 14.78 | <0.001  |
| Age groups, years (%) | | | |
| 0–45       | 3.51%    | 21.50%          |         |
| 46–65      | 38.60%   | 43.41%          |         |
| >65        | 57.89%   | 33.09%          |         |
| Sex        |          |                 | 0.155   |
| Female     | 57.9%    | 48.5%           |         |
| Male       | 42.1%    | 51.5%           |         |
| Baseline comorbidities | | | |
| Hypertension | 45.61%   | 37.95%          | 0.234   |
| Diabetes mellitus | 28.07%   | 19.49%          | 0.102   |
| COPD       | 8.77%    | 3.06%           | 0.030   |
| Stage operation | 5.26%   | 0.24%           | <0.001  |
| Postoperative infection | | | |
| Urinary tract infection | 19.30%   | 2.37%           | <0.001  |
| Sepsis     | 33.33%   | 6.82%           | <0.001  |
| Pneumonia  | 19.30%   | 1.23%           | <0.001  |
| Surgical site infection | 0.03%   | 1.75%           | 0.016   |
| Any infection | 61.40%   | 25.27%          | <0.001  |
| Additional postoperative prescription | | | |
| Proton pump inhibitor | 29.82%   | 15.07%          | 0.002   |
| H2 blocker | 89.46%   | 81.87%          | 0.136   |
| Lactobacillus | 3.51%   | 1.50%           | 0.211   |
| Antibiotic types | | | |
| 1st generation cephalosporins | 52.63%   | 70.26%          | 0.004   |
| 2nd generation cephalosporins | 48.12%   | 50.94%          | 0.784   |
| 2nd generation cephalosporins | 40.35%   | 15.86%          | <0.001  |
| 3rd generation cephalosporins | 3.51%    | 0.30%           | 0.013   |
| Aminoglycosides | 17.54%   | 12.67%          | 0.269   |
| Penicillins | 22.81%   | 8.17%           | <0.001  |
| Quinolones | 21.05%   | 13.32%          | 0.086   |
| Glycopeptides | 22.81%   | 4.13%           | <0.001  |
| Carbapenems | 5.26%    | 0.75%           | 0.009   |
| Ketolides  | 5.26%    | 1.37%           | 0.043   |
| Others     | 12.28%   | 1.80%           | <0.001  |

### Table 3. *Clostridium difficile* infection incidence according to the duration of antibiotic use and the number of administered antibiotics. CDI: *Clostridium difficile* infection. "The duration of antibiotic use was calculated as the days which the antibiotics were administered, regardless of the number of antibiotics or the route of administration.

| Duration of antibiotic use (day) | Total Cases, No. (%) | CDI, No. | Incidence of CDI (%) | P Value |
|--------------------------------|----------------------|----------|----------------------|---------|
| 7 or less                      | 44802 (62.8%)        | 31       | 0.07                 | 0.201   |
| 8 – 14                         | 21709 (30.4%)        | 21       | 0.10                 |         |
| 15 or more                     | 4811 (6.7%)          | 5        | 0.10                 |         |
| Number of antibiotics          |                      |          |                      |         |
| 1                              | 32047 (44.9%)        | 14       | 0.04                 |         |
| 2                              | 26122 (36.7%)        | 19       | 0.07                 |         |
| 3 or more                      | 13123 (18.4%)        | 24       | 0.18                 |         |
days was defined as the summation of the number of days of administration of each antibiotic in the previous study. The difference in the definition of the duration of antibiotic administration may have resulted in such disparity.

Multiple studies have reported on the risk of perioperative antibiotic prophylaxis and CDI. Prophylactic monotherapy with cefoxitin (second generation cephalosporin) was associated with a higher risk of CDI, and the addition of another antibacterial to cefoxitin further increased the risk. The use of multiple antibiotics rather than the duration of antibiotic treatment was associated with CDI. In the present study, the increased number

### Table 4. Independent risk factors for postoperative Clostridium difficile infection. CI: Confidence Intervals; UTI: Urinary tract infection; SSI: Surgical site infection. *Significant P values < 0.05. $R^2 = 0.159.$

| Risk Factor           | Odds ratio | Lower 95% CI | Higher 95% CI | *P value |
|-----------------------|------------|--------------|---------------|----------|
| Age, years            |            |              |               |          |
| ≤45                   | Ref.       |              |               |          |
| 45–65                 | 4.526      | 1.061        | 19.312        | 0.041*   |
| >65                   | 6.408      | 1.521        | 26.997        | 0.011*   |
| Staged Operation      | 5.336      | 1.417        | 20.087        | 0.013*   |
| Postoperative infection|          |              |               |          |
| Any infection         | 3.215      | 1.849        | 5.589         | <0.001*  |
| UTI                   | 3.538      | 1.698        | 7.371         | 0.001*   |
| Sepsis                | 4.427      | 2.458        | 7.975         | <0.001*  |
| Pneumonia             | 6.096      | 2.793        | 13.303        | <0.001*  |
| Type of Antibiotics   |            |              |               |          |
| 1st generation Cephalosporin | 0.408  | 0.226        | 0.738         | 0.033*   |
| 2nd generation Cephalosporin | 0.600  | 0.328        | 1.095         | 0.096    |
| Quinolone             | 0.379      | 0.180        | 0.796         | 0.038*   |
| Number of Antibiotics |            |              |               |          |
| 1                     | Ref.       |              |               |          |
| 2                     | 2.010      | 0.976        | 4.140         | 0.058    |
| 3 or more             | 2.808      | 1.266        | 6.229         | 0.011*   |

### Table 5. Independent risk factors for postoperative mortality within 30 days after surgery. CI: Confidence Intervals; CDI: Clostridium Difficile infection. *Significant P values < 0.05. $R^2 = 0.284.$

| Risk Factor           | Odds ratio | Lower 95% CI | Higher 95% CI | *P value |
|-----------------------|------------|--------------|---------------|----------|
| CDI                   | 7.717      | 1.670        | 35.662        | 0.009*   |
| Age, years            |            |              |               |          |
| ≤45                   | Ref.       |              |               |          |
| 45–65                 | 1.925      | 1.008        | 3.677         | 0.047*   |
| >65                   | 2.809      | 1.489        | 5.299         | 0.001*   |
| Postoperative infection|          |              |               |          |
| Any infection excluding CDI | 0.660 | 0.440        | 0.988         | 0.044*   |
| Pneumonia             | 2.939      | 1.786        | 4.837         | <0.001*  |
| Type of Antibiotics   |            |              |               |          |
| 1st generation cephalosporins | 0.638  | 0.424        | 0.959         | 0.031*   |
| 2nd generation cephalosporins | 0.597  | 0.394        | 0.904         | 0.015*   |
| 4th generation cephalosporins | 2.910 | 1.483        | 5.707         | 0.002*   |
| Penicillins           | 2.813      | 1.838        | 4.306         | <0.001*  |
| Glycopeptides         | 2.051      | 1.288        | 3.267         | 0.002*   |
| Carbapenems           | 1.878      | 1.089        | 3.238         | 0.023*   |
| Number of antibiotics |            |              |               |          |
| 1                     | Ref.       |              |               |          |
| 2                     | 1.458      | 0.816        | 2.604         | 0.202    |
| 3 or more             | 3.016      | 1.648        | 5.519         | <0.001*  |
of antibiotics was associated with an increased risk of CDI after spinal surgery. The Surgical Infection Society Guidelines on surgical prophylaxis recommend the use of antimicrobial prophylaxis for spinal procedures with or without instrumentation15. They also recommend monotherapy with cefazolin, either used as a single dose or administered up to 24 hours postoperatively15. Clindamycin and vancomycin could be used instead for patients with beta-lactam allergies. None of these antibiotics was associated with an increased risk of CDI in the present study, and therefore, these antibiotics could safely be used for prevention of both surgical site infection and CDI.

Although the surgical antibiotic prophylaxis recommends monotherapy with first-generation cefazolin, other types of antibiotics or multiple drugs were prescribed perioperatively. We identified that prophylactic antibiotics were prescribed in combination in 21% of patients on the day of surgery. Among patients without any postoperative infection, only 30.5% was administered first-generation cefazolin alone for surgical antibiotic prophylaxis. The second-generation cefazolin were used as prophylactic antibiotics in many patients (15.3%), and many hospitals prescribed second-generation cephalosporins as discharge medication after intravenous administration of first-generation cephalosporins (18.2%). Similar pattern of such misuse of antibiotics was previously addressed in 2012 HIRA report on the adherence of surgical prophylaxis protocol. Combination of antibiotics was given to 19.8% of surgical patients, and 16.4% was given antibiotics as discharge medication16.

Similar to the results of the previously published papers on CDI after spinal surgery, we identified advanced age and postoperative infection, including urinary tract infection, as significant risk factors20–22. The Surgical Infection Society guidelines on surgical prophylaxis recommend the use of antimicrobial prophylaxis for spinal procedures with or without instrumentation23. They also recommend monotherapy with cefazolin, either used as a single dose or administered up to 24 hours postoperatively23. Clindamycin and vancomycin could be used instead for patients with beta-lactam allergies. None of these antibiotics was associated with an increased risk of CDI in the present study, and therefore, these antibiotics could safely be used for prevention of both surgical site infection and CDI.

A novel finding in this study was that staged operations were shown to be an independent risk factor for CDI. Staged operation accounted for 0.2% of the cases, and it was associated with 5.336 times higher risk of CDI. Recently, the number of adult spinal deformity surgeries is rapidly increasing, and circumferential spine fusion is performed frequently18,19. Because these procedures are complex and the prolonged operation time poses significant burden on the patients, the surgeries are often performed in a staged manner20. Therefore, patients who receive staged operations may need more meticulous patient care and monitoring for development of postoperative complications, including CDI. Also, unlike in previous reports on CDI after spinal surgery, we subdivided postoperative infection into any infection, urinary tract infection, sepsis, and pneumonia, and confirmed that all types of postoperative infection were risk factors for CDI.

Many studies have reported that CDI increases the length of hospitalization, medical cost, and mortality6,21. Similarly, we found that CDI increased mortality rate after spinal surgery by more than seven-fold, and CDI was associated with increased hospital stay and escalated treatment costs. The global surge in the incidence of hyper-virulent C. difficile 027/B1/NAP1 subtype is likely to produce a significant burden on the health care system in the near future13,22.

The incidence of CDI after spinal surgery has been reported as 0.08–0.11%6–8. Our study found that the CDI incidence within 30 days after spinal surgery was 0.08%, which was lower than previous results. This disparity may be due to the difference in the definition of CDI. We identified CDI cases as those that satisfied both criteria of a specific diagnostic code and specific antibiotic administration, whereas other studies identified patients with the diagnoses alone6,8, or selected patients based on their medical record7.

There are several limitations in our study. We used administrative data and were unable to review the medical records for confirmation of the diagnosis or the treatment. The insurance claim data did not include individual health and nutritional status, such as body mass index, functional status, or smoking status, and it also did not provide laboratory data, such as hypoalbuminemia. Therefore, the severity or the stage of the conditions could not be investigated. Another inherent limitation of HIRA data is that there could be discordance between the diagnoses entered in the system and the actual health status of the patient, especially for mild conditions. Therefore, we could not calculate the comorbidity index and analyze its association with the CDI incidence. HIRA-NIS data includes insurance claim data of 13% of randomly selected inpatients, and each sample is labeled with an allocation number. The sample is renewed annually, and since the data is anonymous, a single patient who received operations more than once in different years may be classified as multiple different samples. Although we excluded surgery due to infection, we did not distinguish between trauma, degenerative disease, and congenital deformity. We also could not identify emergency surgeries. Furthermore, even though this study investigated 71,322 patients undergoing spinal surgery, the absolute number of patients (n = 57) with CDI was still low. Finally, our study restricted CIDs to those that occurred within 30 days after spinal surgery. Although many previous studies also used the same definition6,8, CDI has also been reported to occur after more than 30 days after antibiotics administration23.

In conclusion, we found that advanced age, staged operation, postoperative infection, and the use of multiple antibiotics were independent risk factors for CDI after spinal surgery. Although the incidence was low (0.08%), CDI was associated with negative outcomes of increased hospital stay, increased medical cost, and increased mortality. Therefore, modifiable risk factors should be minimized in order to prevent CDI and to optimize surgical outcome after spinal surgery. In particular, the unnecessary use of multiple antibiotics should be avoided.

Methods

Database and data collection. The National Health Insurance (NIH) covers about 98% of the South Korean population24. The data of the Health Insurance Review and Assessment Service (HIRA) includes information on patient diagnoses, past medical or surgical history, treatment procedures, and prescription dispensing information. We used the National Inpatient Sample of the HIRA (HIRA-NIS), which contains claims data of 13%
of randomly selected inpatients. Data of patients who underwent spinal surgery from 2012 to 2016 were collected; those with spinal infections were excluded. Of the 71,761 patients, 293 patients were excluded due to spine-related infections and 146 patients were excluded from other types of infections.

The procedural codes of spinal surgery used in this study are described in Table 6. Outpatient based procedures such as vertebroplasty, kyphoplasty, neuroplasty and nerve block were excluded.

Presumed surgery-related CDI patients were identified as those diagnosed with enterocolitis due to *C. difficile* (International Classification of Diseases, Tenth Revision [ICD-10], diagnosis code A04.7.) and required administration of drugs used for CDI, such as metronidazole or vancomycin, within 30 days of spinal surgery.

Because HIRA-NIS data is a random sample and the sample population is renewed every year, we excluded patients who had surgery in December of each year for whom 30-day follow-up was not possible. According to the data from 2001 to 2010 in the United States, the incidence of CDI was highest in spring and lowest in autumn; therefore, excluding the data for December was unlikely to have a significant impact on the outcomes of our study.

Patients were categorized into two groups: *C. difficile* infected and non-infected. Risk factors, such as age, sex, comorbidities, postoperative infection, spinal surgery procedure, staged operation, the types of antibiotics, and the duration of antibiotic use, were evaluated. Patients were presumed to have received staged operation if they received operation of the same site on different days, no more than 2 weeks apart, of the same hospitalization. The duration of the hospital stay, medical cost, and mortality were also evaluated.

This study was approved by the Institutional Review Board of Severance Hospital. Informed consent of the patients was waived since the study involved a retrospective access to publicly available and anonymized data. All methods were carried out in accordance with relevant guidelines and regulations.

**Statistical Analysis.** Statistical analysis was performed by independent two-sample t-test and chi-square (or Fisher’s exact) test. For continuous variables, the data are expressed as a mean ± standard deviation. For categorical variables, the data are expressed as counts and percentages. To assess potential risk factors for CDI after spinal surgery, a multivariable logistic regression model was created to assess for multivariable predictors of CDI after spinal surgery. A multivariable logistic regression model was also constructed for mortality. Results are reported as odds ratio (OR) and 95% CIs. Risk factors associated with CDI diagnosis were assessed using multivariable logistic regression including all variables. The Hosmer–Lemeshow and model $\chi^2$ goodness of fit tests were used for the model. All statistical analyses were performed with IBM SPSS Statistics for Windows/Macintosh, Version 23.0 (IBM Corp., Armonk, NY, USA). $P$ values < 0.05 were considered significant.

**Data availability**
The data will be available upon reasonable request.

---

**Table 6.** Korea Informative Classification of Diseases procedural codes of spinal surgeries included in the study.

| Procedural codes | Description                              |
|------------------|------------------------------------------|
| N1491            | Diskectomy - Cervical Spine             |
| N1492            | Diskectomy - Thoracic Spine             |
| N1493            | Diskectomy - Lumbar Spine               |
| N2491, N2492     | Cervical Spine Laminoplasty             |
| N1497, N2497     | Laminectomy, Cervical Spine             |
| N1498, N2498     | Laminectomy, Thoracic Spine             |
| N1499, N2499     | Laminectomy, Lumbar Spine               |
| N0466, N1466     | Arthrodesis of Spine - Lumbar Spine     |
| N0468, N1469     | Arthrodesis of Spine - Thoracic Spine   |
| N0469            | Arthrodesis of Spine - Lumbar Spine     |
| N1460, N2470     | Posterior Lumbar Interbody Fusion       |
| N2461, N2463     | Arthrodesis of Spine - Cervical Spine   |
| N2464, N2465, N2466 | Arthrodesis of Spine - Thoracic Spine  |
| N2467, N2468, N2469 | Arthrodesis of Spine - Thoracic Spine  |
| N0451            | Vertebral Corpectomy (Cervical Spine)   |
| N0452            | Vertebral Corpectomy (Thoracic Spine)   |
| N0453            | Vertebral Corpectomy (Lumbar Spine)     |
| N0444, N0445     | Arthrodesis for Spinal Deformity        |
| N0446, N0447     | Arthrodesis for Spinal Deformity        |
| N0303            | Osteotomy (Spine, Pelvis)               |

---
References

1. Redelings, M. D., Sorvillo, F. & Mascola, L. Increase in Clostridium difficile-related mortality rates, United States, 1999–2004. Emerg. Infect. Dis. 13, 1417–1419, https://doi.org/10.3201/eid1309.061116 (2007).
2. Rupnik, M., Wilcox, M. H. & Gerding, D. N. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat. Rev. Microbiol. 7, 526–536, https://doi.org/10.1038/nrmicro2164 (2009).
3. Zerey, M. et al. The burden of Clostridium difficile in surgical patients in the United States. Surg. Infect. 8, 557–566, https://doi.org/10.1089/sur.2006.062 (2007).
4. Martin, B. I. et al. Trends in Lumbar Fusion Procedure Rates and Associated Hospital Costs for Degenerative Spinal Diseases in the United States, 2004 to 2015. Spine 44, 369–376, https://doi.org/10.1097/BRS.0000000000002282 (2019).
5. Deyo, R. A. et al. Trends, major medical complications, and charges associated with surgery for lumbar spinal stenosis in older adults. JAMA 303, 1259–1265, https://doi.org/10.1001/jama.2010.338 (2010).
6. Skovrlj, B., Guzman, J. Z., Silvestre, J., Al Maaih, M. & Qureshi, S. A. Clostridium difficile Colitis in Patients Undergoing Lumbar Spine Surgery. Spine 39, E1167–E1173, https://doi.org/10.1097/BRS.0000000000001487 (2014).
7. Bovonratwat, P. et al. Incidence, Risk Factors, and Impact of Clostridium difficile Colitis After Spine Surgery: An Analysis of a National Database. Spine 43, 861–868, https://doi.org/10.1097/BRS.0000000000002430 (2018).
8. Guzman, J. Z. et al. The Burden of Clostridium difficile after Cervical Spine Surgery. Glob. Spine J. 6, 314–321, https://doi.org/10.1055/s-0035-1562933 (2016).
9. Sartelli, M. et al. WSES guidelines for management of Clostridium difficile infection in surgical patients. World J. Emerg. surgery: WJES 10, 38, https://doi.org/10.1186/s13017-015-0033-6 (2015).
10. Pepin, I. et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin. Infect. Dis. 41, 1254–1260, https://doi.org/10.1086/490896 (2005).
11. Muto, C. A. et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect. Control. Hosp. Epidemiol. 26, 273–280, https://doi.org/10.1086/502539 (2005).
12. Brown, E., Talbot, G. H., Axelrod, P., Provencher, M. & Hoegg, C. Risk factors for Clostridium difficile toxin-associated diarrhea. Infect. Control. Hosp. Epidemiol. 11, 283–290 (1990).
13. Carignan, A. et al. Risk of Clostridium difficile infection after perioperative antibacterial prophylaxis before and during an outbreak of infection due to a hypervirulent strain. Clin. Infect. Dis. 46, 1838–1843, https://doi.org/10.1086/588291 (2008).
14. Kurd, M. F., Pulido, L., Joshi, A., Purtill, J. J. & Parvizi, J. Clostridium difficile infection after total joint arthroplasty: who is at risk? J. Arthroplasty 23, 839–842, https://doi.org/10.1016/j.arth.2007.10.033 (2008).
15. Bratzer, D. W. et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Surg. Infect. 14, 73–156, https://doi.org/10.1089/sur.2013.9999 (2013).
16. Health Insurance Review & Assessment Service. Quality assessment of the use of prophylactic antibiotics for surgery in 2012. http://www.hira.or.kr/ (2012).
17. Kwok, C. S. et al. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am. J. Gastroenterology 107, 1011–1019, https://doi.org/10.1038/ajg.2012.108 (2012).
18. McCarthy, I., Hostin, R., O’Brien, M., Saigal, R. & Ames, C. P. Health economic analysis of adult deformity surgery. Neurosurg. Clin. N. Am. 24, 293–304, https://doi.org/10.1016/j.nec.2012.12.005 (2013).
19. Passias, P. G. et al. Adult Spinal Deformity: National Trends in the Presentation, Treatment, and Perioperative Outcomes From 2003 to 2010. Spine Deform. 5, 342–350, https://doi.org/10.1016/j.jspd.2017.02.002 (2017).
20. Passias, P. G. et al. Comparative safety of simultaneous and staged anterior and posterior spinal surgery. Spine 37, 247–255, https://doi.org/10.1097/BRS.0000000000001766 (2012).
21. Stewart, D. B. & Hollenbeak, C. S. Clostridium difficile colitis: factors associated with outcome and assessment of mortality at a national level. J. Gastrointest. Surg. 15, 1548–1555, https://doi.org/10.1007/s11605-011-1615-6 (2011).
22. Pepin, J., Valiquette, L. & Cossette, B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 173, 1037–1042, https://doi.org/10.1503/cmaj.050978 (2005).
23. Chang, H. T. et al. Onset of symptoms and time to diagnosis of Clostridium difficile-associated disease following discharge from an acute care hospital. Infect. Control. Hosp. Epidemiol. 28, 926–931, https://doi.org/10.1089/ice.2007.151917 (2007).
24. Kim, L., Kim, J. A. & Kim, S. A guide for the utilization of Health Insurance Review and Assessment Service National Samples. Epidemiol. Health 36, e2014008, https://doi.org/10.4178/eph/e2014008 (2014).
25. Argumany, J. R., Aitken, S. L., Lee, G. C., Boyd, N. K. & Reveles, K. R. Regional and seasonal variation in Clostridium difficile infections among hospitalized patients in the United States, 2001-2010. Am. J. Infect. Control. 43, 435–440, https://doi.org/10.1016/j.ajic.2014.11.018 (2015).

Acknowledgements

The authors thank Hye-Won Nam, Marketing Strategy Division of Hannmi Data Science, for providing data.

Author contributions

S.S and B.L. conceived and designed the study. S.S., J.K. and S.L. acquired the data. S.S., H.L. and S.M. contributed to data analysis and interpretation. S.S., J.K., S.L. and B.L. prepared the manuscript. H.L., S.M. and B.L. supervised the study. All authors reviewed and approved the final manuscript.

Competing interests

The authors declare no competing interests.

Additional information

Correspondence and requests for materials should be addressed to B.H.L.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
